MediciNova/$MNOV
1D1W1MYTD1Y5YMAX
About MediciNova
MediciNova Inc is a biopharmaceutical company developing novel therapeutics for the treatment of serious diseases with unmet medical needs and a commercial focus on the United States (U.S.) market. It is currently focused on developing MN-166 (ibudilast) for neurological and other disorders such as progressive multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS), chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and prevention of acute respiratory distress syndrome (ARDS); and MN-001 (tipelukast) for fibrotic and other metabolic disorders such as nonalcoholic fatty liver disease (NAFLD), and hypertriglyceridemia.
- Ticker
- $MNOV
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 6
- Headquarters
- La Jolla, United States
- Website
- medicinova.com
MediciNova Metrics
BasicAdvanced
$71M
-
-$0.22
0.62
-
Price and volume
Market cap
$71M
Beta
0.62
52-week high
$1.96
52-week low
$1.17
Average daily volume
36K
Financial strength
Current ratio
8.754
Quick ratio
8.583
Total debt to equity
0.314
Profitability
EBITDA (TTM)
-11.831
Gross margin (TTM)
37.75%
Net profit margin (TTM)
-1,168.20%
Operating margin (TTM)
-1,287.39%
Effective tax rate (TTM)
-0.06%
Revenue per employee (TTM)
$150,000
Management effectiveness
Return on assets (TTM)
-16.41%
Return on equity (TTM)
-25.56%
Valuation
Price to revenue (TTM)
76.627
Price to book
1.9
Price to tangible book (TTM)
3.09
Price to free cash flow (TTM)
-7.73
Free cash flow yield (TTM)
-12.94%
Free cash flow per share (TTM)
-0.186
Growth
Revenue change (TTM)
583.87%
Earnings per share change (TTM)
-9.16%
3-year earnings per share growth (CAGR)
-5.35%
10-year earnings per share growth (CAGR)
-4.98%
What the Analysts think about MediciNova
Analyst ratings (Buy, Hold, Sell) for MediciNova stock.
MediciNova Financial Performance
Revenues and expenses
MediciNova Earnings Performance
Company profitability
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.